Advertisement
DNA vs WDNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Buy and WDNA is a Buy.
DNA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on DNA as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for DNA just turned positive on October 29, 2026. Looking at past instances where DNA's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
Following a +32.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 90 of 109 cases where DNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where DNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
DNA broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.796) is normal, around the industry mean (3.154). P/E Ratio (-2.242) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
WDNA in upward trend: price rose above 50-day moving average on October 20, 2026
WDNA moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 46 of 53 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on WDNA as a result. In 59 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for WDNA just turned positive on October 27, 2026. Looking at past instances where WDNA's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
The 10-day moving average for WDNA crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +2.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where WDNA advanced for three days, in 213 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 192 of 239 cases where WDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
WDNA broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| DNA | WDNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | N/A |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| Advances ODDS (%) | 4 days ago 84% | 3 days ago 80% |
| Declines ODDS (%) | 2 days ago 90% | 19 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DNA’s FA Score shows that 0 FA rating(s) are green while .
- DNA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DNA’s TA Score shows that 5 TA indicator(s) are bullish.
- DNA’s TA Score: 5 bullish, 4 bearish.
Price Growth
DNA (@Biotechnology) experienced а +12.21% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.
Reported Earning Dates
DNA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (+0.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
WDNA and
Correlation & Price change
A.I.dvisor tells us that WDNA and DNA have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that WDNA and DNA's prices will move in lockstep.
| Ticker / NAME | Correlation To WDNA | 1D Price Change % | ||
|---|---|---|---|---|
| WDNA | 100% | -2.29% | ||
| DNA - WDNA | 24% Poorly correlated | -12.01% | ||
| RVTY - WDNA | 20% Poorly correlated | -5.30% | ||
| A - WDNA | 16% Poorly correlated | -3.47% | ||
| BIO - WDNA | 14% Poorly correlated | -3.18% | ||
| PRAX - WDNA | 14% Poorly correlated | -0.93% | ||
More | ||||